BioSpace News Archive

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), today announced the publication of clinical data from an investigator-initiated trial in patients undergoing lengthy plastic surgery procedure where use of a single sufentanil sublingual tablet 30 mcg (SST; DSUVIA®) in conjunction with intravenous (IV) opioids was able to dramatically reduce postoperative opioid requirements compared to an equivalent dose of opioids administered only via the IV route.

Bold Therapeutics will be presenting at Bio Korea 2022, the largest Life Sciences international convention in Korea, on May 11 to 13, 2022 in Seoul, Korea.

Evofem Biosciences, Inc., announced it has selected Bora Pharmaceuticals Services Inc. Canada as Evofem’s new contract manufacturing organization.

Filterlex Medical Ltd., a cardiovascular medical device startup, announced today that it has completed its CAPTIS First-In-Human (FIH) study. Study results will be presented by Prof. Ran Kornowski, Director of the Cardiology Center at Rabin Medical Center during the EuroPCR conference, 17-20 May, 2022.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2022.

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has developed a novel tear sample collector system and has filed for a provisional patent application for it with the U.S. Patent and Trademark Office.

Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced that Jerry McLaughlin, Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, May 23, 2022, at 3:30 EDT.

NodThera, a clinical-stage biotechnology company developing a new class of potent and selective oral, small molecule NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation, today announced several key advancements across the portfolio. NodThera’s lead candidate, NT-0796, demonstrated positive interim results from its Phase 1 single-ascending dose (SAD) study.

OraSure Technologies, Inc. announced its financial results for the three months ended March 31, 2022.

MediWound Ltd. announced that the Company will release its financial results for the first quarter ended March 31, 2022 on Tuesday, May 17, 2022.